{
    "nct_id": "NCT05336383",
    "official_title": "Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "The presence of any of the following will exclude a subject from enrollment:\n\n1. Subjects in whom salvage chemotherapy is planned less than 14 days after the completion of radiation treatment\n2. Subject is undergoing active treatment for another malignancy other than multiple myeloma\n3. Pregnant women will be excluded from this study.",
    "miscellaneous_criteria": "Inclusion criteria:\n\nSubjects must satisfy the following criteria to be enrolled in the study:\n\n1. Subject is â‰¥ 18 years of age at the time of signing the informed consent form (ICF)\n2. Subject is diagnosed with multiple myeloma\n3. Subject previously received treatment with standard of care BCMA CAR-T cell therapy\n4. Day 30 or later PET scan or other imaging scan after CAR-T infusion shows active disease\n5. Subject has at least one myeloma lesion (plasmacytoma either in bone or soft tissue) that can be treated with radiation\n6. Able to provide informed consent"
}